Agreed. COVID (from a business perspective*) is a

Agreed. COVID (from a business perspective*) is an opportunity that fell into our laps. Once this pandemic is over, we are still primarily an Oncology and autoimmune disease company.

COVID has, and may continue to accelerate our development as a business, but is not critical to our long term success.

My goal (from a business perspective*) is that COVID can provide the exposure and capital needed to accelerate Cytodyns development of its core business. Which, I would point out, is exactly what Nader was stating during the last call. For me, while not an instant gratification statement, is VERY reassuring.

My view (from a business perspective*) is that the sooner we can develop the 40 some odd indications that we appear to be able to treat, the sooner we reach the massive potential of this company. COVID is simply an accelerant.

* I noted business perspective several times, because my primary immediate goal is not business related. We have a moral obligation to save lives irrespective of the impact on our business plan.